Principal Financial Group Inc. Has $43,000 Stock Position in Standard BioTools Inc. (NASDAQ:LAB)

Principal Financial Group Inc. cut its holdings in shares of Standard BioTools Inc. (NASDAQ:LAB) by 29.9% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 22,493 shares of the company’s stock after selling 9,604 shares during the quarter. Principal Financial Group Inc.’s holdings in Standard BioTools were worth $43,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Wolverine Trading LLC acquired a new stake in shares of Standard BioTools during the third quarter worth approximately $27,000. Xponance Inc. purchased a new stake in Standard BioTools in the 2nd quarter worth approximately $34,000. Nisa Investment Advisors LLC boosted its stake in shares of Standard BioTools by 433.8% during the 3rd quarter. Nisa Investment Advisors LLC now owns 18,128 shares of the company’s stock valued at $35,000 after buying an additional 14,732 shares during the period. Creative Planning purchased a new position in shares of Standard BioTools during the 3rd quarter valued at $39,000. Finally, Algert Global LLC acquired a new position in shares of Standard BioTools in the second quarter worth $44,000. Hedge funds and other institutional investors own 53.74% of the company’s stock.

Analysts Set New Price Targets

Separately, TD Cowen reduced their price objective on Standard BioTools from $2.75 to $2.50 and set a “buy” rating for the company in a research report on Thursday, October 31st.

Standard BioTools Trading Down 0.6 %

LAB stock opened at $1.76 on Wednesday. The firm has a market cap of $655.18 million, a PE ratio of -2.48 and a beta of 1.61. Standard BioTools Inc. has a 1 year low of $1.21 and a 1 year high of $3.04. The company has a fifty day simple moving average of $1.87 and a 200 day simple moving average of $1.90.

About Standard BioTools

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.